PDRN Is the Dominant Ingredient Narrative in 2025–2026 K-Beauty — But the Credibility Question Is Unresolved

Polydeoxyribonucleotide (PDRN) — sourced from salmon or, increasingly, plant DNA — has been used clinically for years as a post-procedure skin repair active, typically at concentrations and protocols managed by dermatologists. In 2025–2026 it has become the single most-cited active in new K-beauty launches reaching US retail. Five of the twelve products in The Beauty Signal's May 2026 K-Beauty Product Watch lead with PDRN: COSRX's 5 PDRN Collagen Intense Vitalizing Serum (five distinct PDRN sources, the most complex formulation on the US shelf), Anua's PDRN Collagen Glow Facial Serum Spray (Smart Capsule encapsulation in a mist format), TIRTIR's Matcha Dual Serum (PDRN paired with matcha), numbuzin's No.9 NAD+ BIO Lifting-sil Essence (NAD+ with peptide architecture adjacent to the PDRN narrative), and the broader COSRX 5 PDRN Vital Care Collection now anchoring Amazon.

Brands are explicitly differentiating on three axes. Source count: COSRX's five-source claim is the high-water mark, with most competitors leading on a single salmon-derived source. Delivery technology: Anua's Smart Capsule encapsulation is a format play in a category otherwise dominated by serums and ampoules. Ingredient pairings: matcha-PDRN (TIRTIR), NAD+/peptide (numbuzin), bakuchiol/blue peptide (COSRX's adjacent April 2026 launch). What none of these launches publish is a clinical-grade concentration disclosure — the same data that supports PDRN's use in dermatology clinics.

The structural argument: an active that earned its credibility in a regulated clinical context has been moved into accessible mass retail at $25–$42 price points without the disclosure infrastructure that built its reputation in the first place. The category has not yet resolved how to communicate efficacy claims for an active where dose is the entire point. Watch the next twelve months for either (a) brands voluntarily disclosing concentration in basis points to differentiate, or (b) the first regulatory or consumer-protection challenge to a PDRN efficacy claim. Either is a credibility-defining moment for the ingredient.